ArticleCureus2025
Monoclonal Antibody Treatment for Pediatric Asthma: Current Evidence and Findings From a Delaware Cohort Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Pediatric asthma disproportionately impacts under-resourced, minority youth. Monoclonal antibodies (biologics) are a newer treatment option for moderate to severe asthma. Prior work on biologics in pediatric asthma demonstrates improvements in lung function, exacerbations, subjective symptoms, and the need for steroid bursts, but real-world clinical data are limited. The objective of this study was to characterize the demographic profile and clinical outcomes of a cohort of patients with moderate to severe asthma treated with biologic therapy in a single referral center pediatric pulmonology practice. Methods This IRB-approved chart review included patients 18 or younger treated with biologic therapy for moderate to severe asthma for at least one year at Nemours Children's Hospital, a pediatric referral center in Delaware. Zip code was used to determine the area deprivation index (ADI), with higher scores indicating greater disadvantage. Clinical variables at 12 months prior to and after starting treatment were analyzed using a paired two-tailed Student's t-test, adjusted for multiple comparisons. Results Sixteen patients (56% male, 75% Black, 81% non-Hispanic) met the inclusion criteria. Patients started biologics at a median age of 9.5 years. The median ADI was 73.5 (range 13 to 97). Fifty-six percent of patients had public insurance. Median compliance was 96%, ranging from 63% to 100%. There were statistically significant reductions in the number of hospitalizations for asthma (mean pre: 1.63, post 0.25, t = 4.04, p = 0.01) and courses of oral corticosteroids (mean pre: 5.4, post 2.5, t = 4.46, p <0.01). The frequency of ED visits and results on pulmonary function tests improved but did not reach statistical significance. Conclusions Patients in our cohort were predominantly non-Hispanic and Black and lived in socioeconomically disadvantaged neighborhoods. Within the first year of treatment with a biologic medication, there was a statistically and clinically significant improvement in hospitalizations, oral corticosteroid courses, and subjective asthma symptoms. Medication adherence and tolerance were excellent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.